TRKC, Active Human Recombinant Protein
- Known as:
- TRKC, Active Human Recombinant Protein
- Catalog number:
- 40282
- Product Quantity:
- 10 µg
- Category:
- -
- Supplier:
- Biotech support group
- Gene target:
- TRKC Active Human Recombinant Protein
Related genes to: TRKC, Active Human Recombinant Protein
- Gene:
- NTRK3 NIH gene
- Name:
- neurotrophic receptor tyrosine kinase 3
- Previous symbol:
- -
- Synonyms:
- TRKC
- Chromosome:
- 15q25.3
- Locus Type:
- gene with protein product
- Date approved:
- 1991-07-18
- Date modifiied:
- 2016-10-05
Related products to: TRKC, Active Human Recombinant Protein
Related articles to: TRKC, Active Human Recombinant Protein
- Secretory carcinoma (SC) of the parotid gland is an extremely rare malignant neoplasm in childhood. Given its close clinical and imaging similarities to pleomorphic adenoma, as well as the high potential for diagnostic inaccuracies in fine-needle aspiration cytology (FNAC), preoperative diagnosis is often clinically challenging. Pediatric patients with salivary gland tumors are frequently misdiagnosed, which may lead to unfavorable clinical consequences. - Source: PubMed
Publication date: 2026/05/29
Xu LiHe HuihuaYan HonglinTian XiaoliTang YongfeiYuan Jingping - NTRK-rearranged neoplasms may occur at many body sites. In the female genital tract, they are most common in the uterus with a predilection for the cervix where they often exhibit aggressive behaviour, justifying the designation sarcoma. Typically, these sarcomas are composed of monomorphic spindled cells arranged in fascicular or herringbone patterns. We report two cases of uterine sarcoma (1 cervix, 1 corpus) with next generation sequencing-detected NTRK rearrangements and novel "aberrant" morphologic and immunohistochemical features, including heterologous rhabdomyoblastic and cartilaginous differentiation, negative staining with panTRK and loss of H3K27me3 expression. One case harbored a AKAP13::NTRK3 rearrangement, which has not been previously reported in NTRK-rearranged sarcomas, with co-occurring LZTR1 and TP53 variants. The other case contained hotspot and nonsense variants in DICER1, and was ultimately classified as a DICER1 sarcoma. Our findings expand the morphological and immunohistochemical spectrum of NTRK-rearranged uterine sarcomas, highlight important diagnostic pitfalls and raise the important question of driver versus passenger molecular events. Recognition of tumours with these unusual features is crucial, as NTRK-rearranged sarcomas frequently show aggressive clinical behaviour but are potentially amenable to targeted therapy with selective TRK inhibitors. - Source: PubMed
Publication date: 2026/06/12
Zhang Allen WRazack RubinaDe Wet Daniel RBikwa YemuraiAldera Alessandro PMcCluggage W Glenn - Molecular analysis has emerged as an important ancillary method for the diagnosis and treatment of melanocytic tumors. Test results are often helpful but can occasionally be confounding if an unfamiliar variant is identified. We report a series of melanocytic tumors, which were found to harbor a TFG gene fusion and their significance. Of 105 melanocytic tumors with gene fusions, 9 involved TGF (8.6%). One tumor harbored a TFG::NTRK3 fusion, more precisely characterized as an NTRK3 fusion with TFG as the 5' partner, the detection of which was diagnostically helpful by indicating the presence of a Spitz pathway. Eight cases exhibited a TFG::ADGRG7 fusion. Current evidence suggests that this recurrent event represents a polymorphic germline variant, possibly arising from read-through transcription (intergenic splicing), rather than a biologically pathogenic driver. It should be noted that laboratory reporting practices vary, and not all laboratories report such transcripts in official molecular pathology reports. Recognition of such fusions is essential to avoid misinterpretation, particularly as fusion detection increasingly informs diagnosis and clinical decision-making. These findings underscore the necessity of integrating molecular results with established clinicopathologic frameworks. - Source: PubMed
Publication date: 2026/06/09
Tang HaimingDiNapoli SaraSukhadia PurvilKim DavidBusam Klaus J - Secretory carcinoma is a rare and well-recognized subtype of breast carcinoma generally associated with a favourable prognosis. Although it was initially described in young patients, it is now known to occur at any age and in both sexes. Histologically, it is characterized by a combination of solid, microcystic and tubular architectural pattern with the presence of intracellular and extracellular secretory material that provides its distinctive histological appearance. This tumour is associated with a balanced chromosomal translocation t(12;15) resulting in the ETV6-NTRK3 gene fusion, a translocation rearrangement with well-established oncogenic potential. Secretory carcinoma has traditionally been considered an unusual example of a triple-negative tumour, yet with a favourable clinical outcome. - Source: PubMed
Publication date: 2026/06/09
López-García María ÁngelesGalán LourdesMeléndez BlasEizaguirre BeatrizMasero José ManuelBiscuola MicheleBenavent MartaVieites Begoña - To explore the clinical and pathological characteristics, as well as the immunophenotypes, of facial salivary gland secretory carcinoma and to improve the understanding of this disease. - Source: PubMed
Publication date: 2026/05/26
Qiao ZhouYu WangJianying LiuMengsi Zhang